Proteolytic Processing of ErbB4 in Breast CancerEfficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Pazopanib in the treatment of soft tissue sarcomaDoes a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease.Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for ResA phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityDoxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stuMYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedemaAbsence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.The footprint of the ageing stroma in older patients with breast cancer.Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).Cabozantinib in progressive medullary thyroid cancer.The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status.Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.Tumor volume as an alternative response measurement for imatinib treated GIST patients.Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Biology and management of clear cell sarcoma: state of the art and future perspectives.Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failurePazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsEfficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I.Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trialTherapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.Biological ageing and frailty markers in breast cancer patientsKey Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
P50
Q27670640-C90D7DA9-28FF-4DA4-9843-5598189ED9C1Q27824869-AED65850-4EE4-45B9-8BEC-B675557C04BAQ27851995-79B7C55E-2575-47DD-98EB-5883FA07941FQ28269229-6C322906-825E-4D27-9D47-FAEA982F2276Q33227546-ABCB50EE-BE19-487D-88FA-1B7410516F9DQ33342558-FF1A36BD-179C-40CF-9BFC-F225C33057D9Q33379343-7D68EFD6-00F0-41CB-AE66-EBC8CF9AE0DFQ33385435-3A0C5156-C9D4-4F73-B42A-994F6051B370Q33389572-020E3351-464C-4EE2-ACF2-BC56AA3B7BCDQ33398444-F2B86F14-7726-404D-B85A-07C42D4B9BEFQ33421343-408EEB27-9626-4F73-B09B-D0D5042074FAQ33442988-CCA9E2E2-900C-45F9-8FB9-B7084858E699Q33447149-F400559A-BDB9-4FB9-A099-C1A247F924AFQ33556211-73825ECB-4C0C-44FF-A3F5-448BF84D6A4BQ33561602-E0BB0C5D-3C9A-4F02-A16E-C1E4F969DFC2Q33648995-5A492785-CFEA-4834-B87F-E121D9BAA5D5Q33864284-F56BF73A-610B-4528-8417-3517E24E46F5Q33946929-C42C9005-E238-47C7-BFAA-AD6DA107A695Q33978749-A80A648D-6507-4F9A-BD95-3C7B29941166Q34052411-2DA17601-7C23-4606-A9C6-2645EE92B911Q34069556-1960AA4A-2E14-4312-B6CF-543FD75A9145Q34185084-F69BEE01-C3B0-45AB-B3A5-EB09D18A34F7Q34312415-C475F99A-EC6E-4578-8F97-E4153F0A1CE5Q34380210-863305B2-5030-496E-BCDD-F38BD5067FB6Q34422066-7C9BE2AC-CDD2-47E7-BFE0-69F9F6E626C8Q34469701-ED8F8011-B149-45A7-BF29-975310CC79A6Q34638316-61A3FCE7-7F2E-443D-B019-A2648CBBC671Q34639805-8E3C5E49-FCCC-4D9F-8FB5-6D521EAAE944Q34645665-139A294D-932C-4986-998D-7AABC8F3C0CCQ34677457-7707036E-ECAF-477F-973B-0212BF45C786Q34786553-BAC69919-6725-4031-8EE6-5AAF3E7DE3A1Q35001643-4B7CEBF4-65B3-4380-B7A5-C23ABD75294AQ35028802-38D5A8E2-A1C1-4677-A91E-2F8855BE7155Q35069657-7C571542-59C3-4F8D-B723-465089555FECQ35079731-4C638856-C49B-4933-9E54-8F90EE4CF39FQ35179045-9C8340FB-18DC-4783-977A-67AD4954C47AQ35244168-68959DF2-4BF3-4E7E-A5FF-44F7127AC391Q35555471-DD6C3299-4C9C-49C6-9D9C-9FABB74009CDQ35744970-A37B5888-813E-4374-BF68-5D3F573E793AQ35820539-658183C9-B590-4BCE-95FB-83269DC66924
P50
description
German oncologist
@en
German oncologist
@en-ca
German oncologist
@en-gb
oncoloog
@nl
oncólogo alemán
@es
طبيب أورام ألماني
@ar
name
Patrick Schöffski
@ast
Patrick Schöffski
@en
type
label
Patrick Schöffski
@ast
Patrick Schöffski
@en
prefLabel
Patrick Schöffski
@ast
Patrick Schöffski
@en
P214
P227
P106
P19
P21
P213
0000 0000 2120 5102
P214
P227
P31
P569
1963-12-27T00:00:00Z
P735
P7859
viaf-40480449